Arm II (erdafitinib, atezolizumab) for Bladder Cancer

Study Summary

This phase II trial test whether erdafitinib with or without atezolizumab works in treating patients with bladder cancer that invades the muscular wall of the bladder and has a change or alteration in a specific gene called the FGFR. This alteration of the FGFR gene causes bladder cancer cells to grow and divide abnormally. The usual treatment for someone with bladder cancer invading the muscular wall is chemotherapy with a drug called cisplatin. However, half of the patients cannot get cisplatin due to safety concerns. Erdafitinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This may help keep cancer cells from growing and may kill them. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving the combination of erdafitinib and atezolizumab may help to shrink tumor cells at the time of surgery more than treatment with erdafitinib alone.

Treatment Effectiveness

Study Objectives

Trial Safety

Trial Design

Trial Logistics

Eligibility Criteria